查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1412445

Guillain-Barré二氏症候群市場：按類型、治療方法、最終用戶分類 - 全球預測 2024-2030

Guillain-Barre Syndrome Market by Type, Treatment, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年Guillain-Barré二氏症候群市場規模為6.3443億美元，2024年將達到6.6539億美元，2030年將達到7.3424億美元，複合年成長率為2.10%。

Guillain-Barré二氏症候群的全球市場

主要市場統計
基準年[2023] 63443萬美元
預測年份 [2024] 66539萬美元
預測年份 [2030] 7.3424億美元
複合年成長率（%） 2.1%
格林巴利症候群市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估Guillain-Barré二氏症候群市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對Guillain-Barré二氏症候群市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-Guillain-Barré二氏症候群市場的市場規模和預測是多少？

2-在Guillain-Barré二氏症候群市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-格林-Guillain-Barré二氏症候群市場的技術趨勢和法律規範是什麼？

4-Guillain-Barré二氏症候群市場主要供應商的市場佔有率是多少？

5-進入Guillain-Barré二氏症候群市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球Guillain-Barré二氏症候群的普及增加
      • 擴大採用靜脈注射免疫球蛋白治療Guillain-Barré二氏症候群
      • 消費者醫療保健意識和支出不斷提高
    • 抑制因素
      • 昂貴的治療費用和藥物費用
    • 機會
      • Guillain-Barré二氏症候群的治療進展
      • 罕見疾病政府優惠報銷政策
    • 任務
      • 疾病診斷和治療意識下降
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章Guillain-Barré二氏症候群市場：依類型

  • 急性發炎去髓鞘化神經病變
  • 急性運動感覺軸突神經病變
  • 急性運動軸突神經病變
  • 米勒-費雪綜合症

第7章Guillain-Barré二氏症候群治療市場

  • 治療方法
  • 藥品
  • 物理治療
  • 血漿置換

第 8 章Guillain-Barré二氏症候群市場：依最終用戶分類

  • 診斷中心
  • 醫院

第9章 美洲Guillain-Barré二氏症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區Guillain-Barré二氏症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲Guillain-Barré二氏症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Akari Therapeutics Plc
    • Annexon Inc.
    • Cellenkos Inc.
    • CSL Limited
    • CuraVac Europe SA
    • Electrical Geodesics Inc.
    • Grifols SA
    • Hansa Biopharma
    • Kedrion Biopharma Inc.
    • Octapharma AG
    • Takeda Pharmaceutical Company Limited
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-450A0628D9A1

[180 Pages Report] The Guillain-Barre Syndrome Market size was estimated at USD 634.43 million in 2023 and expected to reach USD 665.39 million in 2024, at a CAGR 2.10% to reach USD 734.24 million by 2030.

Global Guillain-Barre Syndrome Market

KEY MARKET STATISTICS
Base Year [2023] USD 634.43 million
Estimated Year [2024] USD 665.39 million
Forecast Year [2030] USD 734.24 million
CAGR (%) 2.1%
Guillain-Barre Syndrome Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Guillain-Barre Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Guillain-Barre Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Guillain-Barre Syndrome Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics Plc, Annexon Inc., Cellenkos Inc., CSL Limited, CuraVac Europe S.A., Electrical Geodesics Inc., Grifols S.A., Hansa Biopharma, Kedrion Biopharma Inc., Octapharma AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Guillain-Barre Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Acute Inflammatory Demyelinating Polyneuropathy
    • Acute Motor & Sensory Axonal Neuropathy
    • Acute Motor Axonal Neuropathy
    • Miller Fisher Syndrome
  • Treatment
    • Hydrotherapy
    • Medication
    • Physical Therapy
    • Plasmapheresis
  • End-User
    • Diagnostic Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Guillain-Barre Syndrome Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Guillain-Barre Syndrome Market?

3. What are the technology trends and regulatory frameworks in the Guillain-Barre Syndrome Market?

4. What is the market share of the leading vendors in the Guillain-Barre Syndrome Market?

5. Which modes and strategic moves are suitable for entering the Guillain-Barre Syndrome Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Guillain-Barre Syndrome Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of Guillain-Barre syndrome worldwide
      • 5.1.1.2. Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
      • 5.1.1.3. Rising consumer healthcare awareness and expenditures
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of treatment and drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in management of Guillain-Barre syndrome
      • 5.1.3.2. Favorable governmental reimbursement policies for rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Less awareness towards disease diagnosis and treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Guillain-Barre Syndrome Market, by Type

  • 6.1. Introduction
  • 6.2. Acute Inflammatory Demyelinating Polyneuropathy
  • 6.3. Acute Motor & Sensory Axonal Neuropathy
  • 6.4. Acute Motor Axonal Neuropathy
  • 6.5. Miller Fisher Syndrome

7. Guillain-Barre Syndrome Market, by Treatment

  • 7.1. Introduction
  • 7.2. Hydrotherapy
  • 7.3. Medication
  • 7.4. Physical Therapy
  • 7.5. Plasmapheresis

8. Guillain-Barre Syndrome Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals

9. Americas Guillain-Barre Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Guillain-Barre Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Guillain-Barre Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Akari Therapeutics Plc
    • 13.1.2. Annexon Inc.
    • 13.1.3. Cellenkos Inc.
    • 13.1.4. CSL Limited
    • 13.1.5. CuraVac Europe S.A.
    • 13.1.6. Electrical Geodesics Inc.
    • 13.1.7. Grifols S.A.
    • 13.1.8. Hansa Biopharma
    • 13.1.9. Kedrion Biopharma Inc.
    • 13.1.10. Octapharma AG
    • 13.1.11. Takeda Pharmaceutical Company Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GUILLAIN-BARRE SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GUILLAIN-BARRE SYNDROME MARKET DYNAMICS
  • FIGURE 7. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GUILLAIN-BARRE SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR & SENSORY AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MILLER FISHER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 146. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. GUILLAIN-BARRE SYNDROME MARKET LICENSE & PRICING